Organization
Beijing Cancer Hospital & Institute
11 abstracts
Abstract
Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).Org: Laboratory of Carcinogenesis and Translational Research of the Ministry of Education, Beijing Cancer Hospital & Institute, Ningbo Newbay Technology Development Co., Ltd.,
Abstract
Camrelizumab plus apatinib and temozolomide as first-line therapy for advanced acral melanoma: 2-year survival results from CAP 03.Org: Department of Melanoma and Sarcoma Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Melanoma Institute Australia, Department of Genitourinary Oncology,
Abstract
Use of integrated multi-omics analysis to determine antitumor efficacy of donafenib in combination with FADS2 inhibition in hepatocellular carcinoma.Org: Beijing Cancer Hospital & Institute, Department of Interventional Therapy, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China,
Abstract
Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.Org: Dana-Farber Cancer Institute, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Bristol Myers Squibb, Institut Curie, Saint Cloud, France, McGill University Health Center,
Abstract
Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study.Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Peking University First Hospital, Affiliated Drum Tower hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, China,
Abstract
Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors.Org: Beijing Cancer Hospital & Institute, Cancer Hospital of Shantou University Medical College, Central Hospital Affiliated to Shandong First Medical University, Jinan, China, Luoyang Center Hospital, Department of Medical Oncology, Zibo Municipal Hospital, Zibo, China,
Abstract
A deep learning model for the prediction of microsatellite instability and pathogenic POLE mutations in colorectal cancer using histopathologic images.Org: Department of GI Oncology, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Peking University Cancer Hospital & Institute, Beijing Advanced Innovation Center for Big Data and Brain Computing, Beihang University,
Abstract
Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321 + pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors.Org: Dana-Farber Cancer Institute, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Georgetown University Hospital, Washington, DC, Lombardi Comprehensive Cancer Center, START San Antonio,
Abstract
Anti-tumor activity of sunvozertinib in NSCLC with EGFR sensitizing mutations after failure of EGFR TKI treatment.Org: Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijng, China, Chi Mei Chest Hospital, Department of Oncology, National Cheng Kung University Hospital, Blacktown Hospital, St. George Hospital,
Abstract
The preventive effect of celecoxib on regorafenib-associated hand-foot syndrome in patients with liver metastasis from colorectal cancer: A single-center, retrospective, real-world study.Org: Beijing Cancer Hospital & Institute, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China,
Abstract
The phase 1 clinical trial of anti–PD-1 (pucotenlimab) plus intrahepatic injection of oncolytic virus (OH2) combined with radiotherapy of liver metastasis in stage IV melanoma.Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Beijing Cancer Hospital & Institute,